Alprazolam transdermal - Crescita Therapeutics

Drug Profile

Alprazolam transdermal - Crescita Therapeutics

Alternative Names: Alprazolam transdermal formulation; ZRS 101

Latest Information Update: 06 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZARS
  • Developer Crescita Therapeutics
  • Class Anxiolytics; Benzodiazepines; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Panic disorder

Most Recent Events

  • 06 May 2016 Chemical structure information added
  • 13 May 2011 ZARS Pharma has been acquired by Nuvo Research
  • 28 Aug 2006 Preclinical trials in Panic disorder in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top